Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.05 HKD | -1.72% | -4.52% | -1.96% |
Mar. 27 | China Production Bases of Shyndec Pharmaceutical's Unit Gets Compliance Certification from Australian Regulator | MT |
Mar. 25 | Sinopharm's Attributable Profit Jumps in 2023 on Higher Revenue | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.13 for the 2023 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.96% | 8.14B | C | ||
+16.48% | 70.86B | C+ | ||
+11.65% | 27.37B | C+ | ||
+1.91% | 7.92B | B | ||
-25.23% | 7.51B | B- | ||
+1.40% | 4.65B | B- | ||
+10.56% | 4.08B | B+ | ||
+3.16% | 4.12B | B | ||
-4.65% | 3.92B | B- | ||
+11.60% | 3.33B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Sinopharm Group Co. Ltd. - Hong Kong S.E.
- Ratings Sinopharm Group Co. Ltd.